Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference
February 05, 2019 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies
October 04, 2018 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J. and HOUSTON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC, Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company...
Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia
April 17, 2018 09:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
April 16, 2018 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting
March 15, 2018 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...